





Cells 2021, 10, 233. https://doi.org/10.3390/cells10020233 www.mdpi.com/journal/cells 
Review 
Intracellular Sources of ROS/H2O2 in Health and  
Neurodegeneration: Spotlight on Endoplasmic Reticulum 
Tasuku Konno 1,*, Eduardo Pinho Melo 2, Joseph E. Chambers 3 and Edward Avezov 1,* 
1 Department of Clinical Neurosciences and UK Dementia Research Institute, University of Cambridge,  
Cambridge CB2 0AH, UK 
2 CCMAR-Centro de Ciências do Mar, Campus de Gambelas, Universidade do Algarve, 8005-139 Faro,  
Portugal; emelo@ualg.pt 
3 Cambridge Institute for Medical Research, University of Cambridge, Cambridge CB2 0XY, UK; 
jec202@cam.ac.uk 
* Correspondence: tk549@cam.ac.uk (T.K.); ea347@cam.ac.uk (E.A.) 
Abstract: Reactive oxygen species (ROS) are produced continuously throughout the cell as products 
of various redox reactions. Yet these products function as important signal messengers, acting 
through oxidation of specific target factors. Whilst excess ROS production has the potential to 
induce oxidative stress, physiological roles of ROS are supported by a spatiotemporal equilibrium 
between ROS producers and scavengers such as antioxidative enzymes. In the endoplasmic 
reticulum (ER), hydrogen peroxide (H2O2), a non-radical ROS, is produced through the process of 
oxidative folding. Utilisation and dysregulation of H2O2, in particular that generated in the ER, 
affects not only cellular homeostasis but also the longevity of organisms. ROS dysregulation has 
been implicated in various pathologies including dementia and other neurodegenerative diseases, 
sanctioning a field of research that strives to better understand cell-intrinsic ROS production. Here 
we review the organelle-specific ROS-generating and consuming pathways, providing evidence 
that the ER is a major contributing source of potentially pathologic ROS. 
Keywords: reactive oxygen species; hydrogen peroxide; endoplasmic reticulum; redox signalling; 
antioxidants; neurodegeneration; dementia 
 
1. Introduction 
Substantial quantities of reactive oxygen species (ROS), H2O2 in particular, are 
produced intracellularly. H2O2 is generated endogenously as a functional entity and as a 
by-product of reducing/oxidising (redox) chemistry: H2O2 can be generated by regulated 
enzymatic processes to serve as a signal molecule, fuel protein disulfide bonding or as a 
controlled toxin in immunological-activity. Imperfections in electrochemical reactions can 
result in unintended H2O2/ROS (e.g., mitochondrial respiration chain with oxygen as 
terminal electron acceptor). Some ROS, specifically free radicals, are short-lived as a 
product of their high reactivity with biological macromolecules, including nucleic acids 
and lipids, which in turn can render them hazardous. By contrast, H2O2, a non-radical 
ROS, is less reactive with biomolecules and as such has a relatively long biological lifespan 
(cellular half-life of ~1 ms) [1,2]. Yet H2O2 is also capable of producing harmful radicals, 
through fenton chemistry [3]. Therefore, ROS generating pathways have co-evolved with 
mechanisms to control their spatio–temporal distribution. Thus, cellular compartments 
handling the protein-encoding nucleic acids maintain a strictly reducing environment 
(redox potential estimated at −300 mV and −280 mV in the nucleus and cytoplasm, 
respectively [4]) (see glossary). These compartments are equipped with ROS quenching 
enzymes, e.g., catalase and glutathione peroxidases. The reducing nature of such 
environments allows transient and localised usage of H2O2 as a second messenger. As 
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such, H2O2 complements the cell’s repertoire of second messengers as it can induce rapid 
and reversible functional changes to proteins through intra/inter molecular disulfide 
bonding and other cysteine modifications such as sulfenylation and sulfonation. This 
principle is exemplified by a bacterial H2O2 sensing system, where the key protein, OxyR 
contains a peroxidatic cysteine residue, surrounded by positive charges, that is 
preferentially reactive with H2O2. This reaction results in a sulfenic intermediate that is 
highly reactive with the thiolate of a second “resolving” cysteine, producing an 
intramolecular disulfide that converts the protein into a functional transcription factor 
that activates the production of ROS-antagonising enzymes [5]. The kinetic advantage of 
H2O2, in such a system, over the reducing forces of the cell allows this reaction to prevail 
even when its concentration is 2–3 orders of magnitudes lower than the antagonising 
reductants [6]. As such, OxyR has been utilised as a template in engineering a genetically 
encoded fluorescent H2O2 probe, HyPer, sensitive to physiological H2O2 concentrations 
[7]. 
The short-lived nature of H2O2 relative to the biomolecules it reacts with and the 
overwhelming cellular reductive force ensure the locality and transience of H2O2-
mediated signalling events. Several signalling pathways of mammalian cells take 
advantage of this chemistry, enzymatically producing local H2O2 that can activate factors 
such as kinases. For instance, oxidation of cysteine residues in SRC, a proto-oncogene non-
receptor tyrosine kinase, activates this enzyme, regulating cell proliferation and survival 
by activating downstream pathways such as ERK and AKT signalling [8]. Several 
transcription factors, such as NF-κB and KEAP1-NRF2, also sense H2O2 to activate 
transcriptional programs [9,10]. 
The reducing, ROS disfavouring environment of the nucleus, cytoplasm and 
mitochondria contrasts with a relatively oxidising milieu in the organelles of the secretory 
pathway. The endoplasmic reticulum (ER) lumen, in particular, maintains an oxidising 
environment similar to that of the extracellular conditions. This is favoured by the 
relatively oxidising reduction potential of glutathione (EGSH/GSSG), a measure of redox 
conditions, estimated at −208 mV in the ER [11,12]. Moreover, the ER maintains a 
relatively high turn-over of H2O2 as its oxidative protein folding machinery both produces 
and utilises H2O2 continuously. H2O2 apparent confinement to the ER (discussed herein) 
can be compromised when redox homeostasis is perturbed [13,14]. 
This notion places the ER in the spotlight as a potential source of ROS associated with 
pathologies, including those associated with neurodegenerative diseases. Excessive ROS 
load entails damage of structural and functional macromolecules including lipids, 
protein, RNA, and perhaps with the most severe repercussions to DNA, where a single 
unrepaired damage event can impact on all its downstream products. As such, 
compromised insulation of organelles that maintain naturally high ROS (such as ER) may 
contribute to pathological elevations in ROS. 
With an emphasis on the ER, here we review the findings contributing to the current 
understanding of organelles’ ROS producing/consuming pathways and discuss how an 
imbalance in the activity of ROS generating and antagonising pathways as well as 
organellar ROS permeability dysregulation can lead to an increase in their steady-state 
load. The intracellular sources of H2O2 are discussed in the context of their association 
with neurodegenerative diseases. 
2. ER Sources of ROS/H2O2 
The ER is devoid of ROS-vulnerable genetic material and therefore, predictably, can 
tolerate a high abundance of ROS. In addition, H2O2 reactivity with most protein 
functional groups is energetically unfavourable, suggesting it is unlikely to significantly 
contribute to protein misfolding directly [15]. ER oxidative protein folding both generates, 
and is at least partially fuelled by, H2O2 (described in detail below) and basal ER ROS 
content is reported to be relatively high [13]. This is unsurprising, as approximately 30% 
of cellular proteins enter the ER, many of them en route to the cell membrane or secretion. 
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A 1970s ex vivo study using rat liver homogenate reports that H2O2 in the microsomal 
fraction, which contains the ER predominantly, accounts for 45% of the cell total, three 
times that derived from mitochondrial extracts of the same samples [16,17]. Thus, the ER 
appears uniquely capable of producing and utilising H2O2 as fuel for enzymatic oxidative 
folding process on a massive scale. 
The core of the ER oxidative folding machinery is a group of oxidoreductase-
chaperone enzymes of the protein disulphide isomerase (PDI) family, which functionally 
interact with their substrates via redox-active CXXC motifs of their catalytic thioredoxin 
domains (Figure 1) [18]. PDI itself catalyses disulphide bond formation in substrate 
proteins, leading to reduction of PDI CXXC motifs that are in turn reoxidised by ER 
oxidoreductin 1 (ERO1). The later produces H2O2 as two electrons per thiol pair flow from 
PDIs to molecular oxygen [19]. In this process, ERO1 is estimated to consume 25% of the 
oxygen available in the cell [20–22]. Yet the by-product of this reaction, H2O2, can be 
consumed by another process that drives PDI reoxidation, catalysed by the ER-localised 
peroxiredoxin PRDX4 (pathway described below). Notably, even though ERO1 gene 
expression is up-regulated in response to stimuli such as hypoxia and the unfolded 
proteins response (UPR) [23–26], knockdown of ERO1 gene leads to a resistance to 
tunicamycin-induced ER stress in worms and ER stress-induced apoptosis in mouse 
macrophages [27,28]. It seems that up-regulation of ERO1 results in excessive ROS 
production rather than improving oxidative folding capacity. Indeed, excess of ERO1 
activity caused by hyperactive mutants or overexpression has been reported to increase 
ROS production and cell death [29,30]. Noteworthily, knockdown of ERO1 in worms 
extends their lifespan by 32% and is accompanied by a reduction in peroxide levels [31]. 
Thus, through its role in oxidative protein folding, excessive ERO1 activity contributes to 
an ER-emanating ROS hazard. 
Although ERO1 deficit is lethal in yeasts [32,33], this gene is at least partially 
dispensable in mammals (knockout of all ERO1 isoforms, Ero1a and Ero1b, gives rise to 
only a mild phenotypic defect in mice [34,35]). In the absence of ERO1, the oxidative 
folding process can be sustained by peroxiredoxin 4 (PRDX4), an ER-localised 
antioxidative enzyme that catalyses PDI reoxidation [36]. PRDX4 scavenges H2O2, forming 
water with the concomitant relay of oxidative equivalent to PDIs (Figure 1). In normal 
conditions, PRDX4 works presumably in parallel to ERO1 in oxidative recycling of PDI. 
Fuelled by H2O2 generated as a by-product of ERO1 activity, PRDX4 seems to work 
alongside ERO1 as a wasteless system of transferring electrons from cysteine thiols to 
oxygen generating water in the process. The robustness of ER oxidative protein folding in 
higher organisms may be in part attributed to the evolutionary acquisition of these 
parallel pathways (the PDI-PRDX4 pathway is absent in yeast [36]). As such, ER-
accumulation of H2O2 that could have detrimental effects in other cellular compartments 
is dealt with “in house” by the ER, through a mechanism that further promotes oxidative 
protein folding capacity. 
The triple knockout mouse model that lacks Prdx4, Ero1a and Ero1b is viable, whilst 
showing a compromised oxidative folding kinetics [6] and a scurvy-like phenotype, 
presumably due to impaired collagen maturation [37]. This provides evidence to support 
that additional proteins are capable of driving oxidative protein folding in the ER 
(Figure1). 




Figure 1. Schema of pathways producing and utilising endoplasmic reticulum (ER)-derived H2O2. Reduced thiols (-SH) of 
cysteine residues in nascent proteins are oxidised by catalytically competent protein disulphide isomerase (PDI)s to 
promote protein folding with native disulphide bonds (S-S). PDI can be re-oxidised by ERO1, with flavin adenine 
dinucleotide (FAD) embedded in its active site, which reduces molecular oxygen (O2) to hydrogen peroxide (H2O2). ER-
resident antioxidants PRDX4, GPX7, and GPX8 oxidise their catalytic domain by utilising H2O2 (-SOH = sulfenic acid) and 
mediate “the disulphide relay” to PDI. NOX4 produces H2O2 over superoxide on the ER membrane, unlike other NOX 
family proteins. 
The importance of PRDX4-mediated H2O2 quenching in the ER is highlighted by 
phenotypic consequences of its genetic manipulation: Its overexpression led to protection 
against glutamate-induced neuronal cell death, increased insulin production, and 
inhibition of adipogenesis [38–40]. Prdx4 knockout mice showed phenotypes such as 
abnormal spermatogenesis and susceptibility to drug-induced colitis, indicating a 
systemic requirement for this protein [41,42]. Moreover, the expression level of PRDX4 
positively correlates with the prognosis of patients with lung adenocarcinoma [43]. The 
apparent ability of cells to maintain ER oxidative protein folding in the face of PRDX4 loss 
suggests that ERO1 activity is likely sufficient to perform this function, albeit driving 
further H2O2 production. 
Besides PRDX4, ER H2O2 is also utilised by ER-resident glutathione peroxidases, 
GPX7 and GPX8 (ER luminal and lumen-facing membrane anchored, respectively [44]). 
Both can oxidise PDI in the presence of H2O2 and interact with ERO1, catalysing oxidative 
protein folding [29,44,45]. They can also protect insulin-secreting cells from ER stress 
induced by saturated fatty acids (FFAs) [45]. Metformin, a therapy for diabetes, is reported 
to provide antiaging and cognitive decline-diminishing benefits that are thought to be 
mediated by the upregulation of GPX7 [46]. Maintaining GPX7 levels seems to be 
important to protect from hyperactivation of ERO1 and ER stress triggered by 
homocysteine, which causes hyperhomocysteinemia-related vascular diseases [47]. Gpx7 
knockout mice show systemic oxidative stress, carcinogenesis and shortened lifespan [48]. 
Given that GPX7 can protect both the ER and nuclear DNA from oxidative damage, the 
effects of ER ROS appear to reach beyond the lumen of the organelle [49]. Supporting this 
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view, removal of GPX8 increases H2O2 levels in the cytosol, indicating that GPX8 may play 
a role in preventing leakage of H2O2 from the ER [14]. 
The membrane localised enzyme NADPH oxidase 4 (NOX4) provides another source 
of ER H2O2. This enzyme preferentially produces H2O2 rather than superoxide through a 
highly conserved histidine residue in its extracytosolic loop (E-loop), not present in other 
NOX family proteins [50]. NOX4-derived H2O2 drives multiple biological events inside 
and outside the ER (e.g., Ras signalling activation through ER Ca2+ efflux by 
sarco/endoplasmic reticulum calcium-ATPase (SERCA) oxidation [51,52], H2O2 traversal 
of ER membrane in this extra-ER activity is likely mediated by aquaporins, see discussion 
in the next section). Although NOX4 is found in other organelles, this protein has been 
shown to be predominantly expressed on the ER membrane in human neuroblastoma SH-
SY5Y cells, human hepatocyte Hep G2 cells, and human umbilical vein endothelial 
(HUVEC) cells [51,53]. NOX4 interacts with calnexin, an ER membrane lectin-chaperone, 
with a degree of dependence on this factor: elimination of calnexin reduces NOX4 
expression level as well as ROS production [54]. Moreover, NOX4 also interacts with PDI 
[55], and its interaction controls uncoupling of endothelial nitric oxide synthase (eNOS) 
and expression of β-galactosidase, which are involved in ageing of vascular endothelial 
cells [56]. 
Protective roles have been suggested for ER-localised NOX4 activity. NOX4 has been 
suggested to drive prolonged integrated stress response signalling by oxidatively 
inhibiting protein phosphatase 1 (PP1) and protecting against acute kidney injury in vivo 
[57].  
The lumen of the ER appears to be endowed with an additional crucial layer of 
controlling H2O2 load. Measurements using an ER-tuned genetically encoded H2O2 sensor 
pointed to the role of reduced glutathione in buffering the load of ER-intrinsically 
generated H2O2 [13]. Relatively high ER-glutathione (approximately 10–15 mM total, 
mostly reduced [58,59]) may compensate for poor kinetics of GSH–H2O2 reactivity. 
Regulation of ER redox by glutathione seems to be mediated by its flux and Ca2+ 
mobilisation, at least in part [60]. However, H2O2-degrading enzymes, such as the ER-
resident PRDX4 and glutathione peroxidases GPX7 and GPX8, are significantly more 
efficient hydrogen peroxide-degrading catalysts than GSH alone. However, above a 
threshold concentration, calculated to be within the range of concentrations at which H2O2 
acts as a second messenger, chemical reduction of H2O2 by GSH becomes kinetically 
competitive with enzymatic activity, aiding the maintenance of H2O2 levels. Accordingly, 
when glutathione is depleted, levels of H2O2 in the ER augment, and the viability of cells 
with reduced cytosolic antioxidant capacity (e.g., a pancreatic β-cell model, with natural 
catalase deficiency) becomes strongly compromised, particularly when H2O2 production 
is further stimulated through the biosynthesis of disulphide-containing substrates (e.g., 
pro-insulin) [13]. This highlights the physiological relevance of the chemical reduction of 
H2O2 by GSH and further suggests that the ER constitutes a significant source of 
pathological ROS. 
H2O2 Transport Across the ER Membrane 
The abundance of H2O2 in the ER suggests that the ER membrane likely limits its 
conductance towards other, potentially more ROS-vulnerable cellular compartments. The 
H2O2 quenching mechanisms on the cytosolic side of the ER membrane likely contribute 
to the insulation. However, mechanistic details of what promotes or limits H2O2 
permeability over membranes remains only partially understood. A view point in favour 
of unlimited H2O2 transit across the ER membrane was expressed [61].  
Since artificially imposed H2O2 removal in other organelles does not affect H2O2 
content of the ER, the influx of H2O2 into the ER from other organelles seems to be tightly 
restricted at steady state [6]. However, in light of measurements showing that ER-derived 
H2O2 can leak to the cytosol under conditions of luminal H2O2 overload, potentially 
causing oxidative damage in other organelles [13,14], transport of ER H2O2 across the 
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membrane is a plausible toxicity-determining parameter. The general principles of 
controlled material exchange between organelles through passive channels or active 
transporters seem to apply in the case of H2O2: aquaporins (AQPs, described initially as 
water channels) have been suggested to conduct H2O2 across membranes [62–65]. 
In mammals, the AQP family of proteins consists of thirteen isoforms. They share a 
common topology of six transmembrane helices, five loops (three extracellular and two 
intracellular), and two highly conserved asparagine–proline–alanine (NPA) motifs. 
Assembled as tetramers, these proteins form an hourglass-like functional pore [66]. They 
are classified by three sub-groups; classical AQPs (AQP0, AQP1, AQP2, AQP4, AQP5, 
AQP6, AQP8), aquaglyceroporins (AQP3, AQP7, AQP9, AQP10), and unorthodox or 
superaquaporins (AQP11, AQP12), based on their substrates. In addition, recently a new 
category—peroxiporins has been identified (AQP1, AQP3, AQP5, AQP8, AQP9, AQP11), 
whose common feature is the ability to transport H2O2 with a degree of preference 
[63,67,68]. It is worth noting that all AQPs can potentially enable transport of H2O2 to some 
extent [69].  
As all AQPs start their journey through the secretory pathway at the ER, each can 
potentially contribute to H2O2 transport across its membrane. Notably, AQP8 was 
explicitly shown to mediate H2O2 transport across the ER membrane [67]. Partial ER-
localisation of AQP4 and AQP9 have also been observed [68]. Further, human AQP11 
showed ER localisation and the capacity to transport H2O2 across the ER membrane 
[70,71]. 
The precise function of peroxiporins on the ER membrane currently remains obscure. 
One can speculate that AQPs may maintain redox homeostasis or even support cellular 
signalling by modulating H2O2 efflux from the ER, as well as the influx to the ER. This is 
indirectly supported by the finding that the expression level of NOX2 and renal oxidative 
damage are augmented in Aqp11 knockout mice [72]. Recent findings on hydrogen 
sulphide (H2S)-mediated regulation of an ER aquaporin’s conductivity support such a 
possibility [73]. 
It is conceivable that regulated and localised H2O2 conductivity of the ER membrane 
may constitute a mechanism for time-space specific releases of H2O2 from its “ER-store”. 
Such a mechanism, hitherto uncharacterized, could be considered analogous to regulated 
calcium releases from ER stores. In the case of the short-lived H2O2 the “storage” is 
afforded by its constant high productions rate in the confined space of the ER.  
3. Non-ER Sources of ROS/H2O2 
3.1. Mitochondrial ROS/H2O2 
Though the mitochondrial matrix maintains a relatively reducing environment 
(redox potential of −300 mV [4]), it is thought to constitute a major source of intracellular 
ROS, as a by-product of its multicomponent electrochemistry machinery. However, only 
15% of total H2O2 was accounted for in a mitochondrial fraction of cell extracts [16,17]. 
This is consistent with the abundant and diverse antioxidant enzymology of the organelle, 
affording protection to other organelles and its precious DNA content from oxidative 
damage.  
Mitochondria synthesise ATP through oxidative phosphorylation, coupled to the 
electron transport chain (ETC). Leakage of electrons from the ETC, as well as other related 
enzymes, leads to a partial reduction of oxygen to form superoxide, and it is subsequently 
converted to H2O2 (a less reactive oxidant) and oxygen by superoxide dismutase 1 (SOD1) 
in mitochondrial intermembrane space, and SOD2 in mitochondrial matrix. Although 
most of the oxygen in the cell is consumed by mitochondria, only 1–2% seems to be 
converted to ROS [17]. Systemic homozygous knockout of SOD2 in mice led to pre-
weaning lethality accompanied by multiple tissue dysfunctions such as cardiomyopathy, 
fatty liver, metabolic acidosis, and neurodegeneration [74,75]. In contrast, overexpression 
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of both SOD2 and catalase protects the cell from antiretroviral-induced oxidative stress 
and cardiomyopathy [76]. 
To date, eleven ETC-related enzymes have been identified as the source of ROS in 
mitochondria [77,78]. Four of them are present in distinct 2-oxoacid dehydrogenase 
complexes, which catalyse the oxidative decarboxylation of different 2-oxoacids to the 
corresponding acyl-CoA and NADH. These are 2-oxoglutarate dehydrogenase complex 
(OGDHC), pyruvate dehydrogenase complex (PDHC), branched-chain 2-oxoacids 
dehydrogenase complex (BCOADHC), and 2-oxoadipate dehydrogenase complex 
(OADHC). ROS production from these complexes seems to be much higher than that from 
complex I, which has been previously considered as one of the major mitochondrial ROS 
sources [79]. Complex I (NADH ubiquinone oxidoreductase) generates H2O2 at a flavin-
containing site and a quinone-binding site. Notably, an improved genetically encoded 
H2O2-specific sensor (HyPer7), detected complex1-derived H2O2, which is driven by its 
selective inhibitor rotenone, appears to be released toward the mitochondrial matrix side 
[80]. The remaining four of the ROS sources are located in dehydrogenases, linked to 
ubiquinone: dihydroorotate dehydrogenase (DHODH), the electron-transferring 
flavoprotein (ETF)–ubiquinone oxidoreductase system (ETF-QO), mitochondrial glycerol-
3-phosphate dehydrogenase (mGPDH) as well as complex II (succinate dehydrogenase, 
SDH). ROS can also emanate from the outer ubiquinone-binding site of complex III [81]. 
Furthermore, mitochondria-localising NADPH oxidase can provide a source of H2O2. 
NOX4 is predominantly localised to mitochondria in certain cells such as mouse 
podocytes, mesangial cells and kidney cortex [82,83]. Mitochondrial NOX4-derived H2O2 
was implicated in ageing-dependent aortic stiffening and drug resistance [84,85].  
Of interest, cardiomyopathy triggered by the ablation of desmin, a major muscle-
specific intermediate filament protein, is ameliorated by catalase overexpression but 
deteriorated by SOD2 overexpression [86]. This can be explained by either augmenting 
mitochondrial H2O2 or diminished superoxide and implies that balancing mitochondrial 
ROS maintains cellular homeostasis. Indeed, mitochondrial ROS seems to regulate 
hypoxic signalling [87]. In addition, mitochondrial ROS are reported to be required for 
expressions of hypoxia-inducible genes such as erythropoietin and Hypoxia-inducible 
factor 1 (HIF-1) [88], as well as enhancing cytosolic calcium levels in pulmonary arterial 
smooth muscle cells (PASMCs) during hypoxic pulmonary vasoconstriction (HPV) 
[89,90]. 
Notably, the majority of proteins in mitochondrial intermembrane space are known 
to contain disulfide bonds as a post-translational modification [91], and an electron relay 
mediated by ERV1, a mitochondrial FAD-linked sulfhydryl oxidase which mediates 
disulfide bond formation, results in H2O2 production analogous to the ERO1-pathway. 
H2O2 produced by ERV1 is scavenged by cytochrome C, likely forming another mode by 
which mitochondria are protected from the toxicity of H2O2 [92]. Uncoupling proteins 
(UCPs), the modulators of thermogenesis by uncoupling mitochondrial proton gradient 
and ATP synthesis, also seem to be important in mitochondrial H2O2 production 
regulation [93–95]. 
3.2. Peroxisomal ROS/H2O2 
Peroxisomes are single-membrane-bounded organelles present in most eukaryotes. 
A variety of oxidation reactions, such as β-oxidation of fatty acids, biosynthesis of 
cholesterol, and metabolism of amino acids and purines are carried out in this organelle. 
Accordingly, the production of peroxisomal ROS is reportedly mediated by: xanthine 
oxidase, D-amino oxidase, urate oxidase, and Acyl-CoA oxidase [96]. Despite its relatively 
small size, the peroxisome is estimated to generate about 35% of total intracellular H2O2 
and therefore is considered as a major source of intracellular ROS [97–99].  
Peroxisomal ROS can function as a signal molecule and seem to be functionally 
associated with autophagy in particular. For instance, the negative regulators of 
mammalian target of rapamycin complex 1 (mTORC1), tuberous sclerosis complex 1 
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(TSC1) and 2 are localised to peroxisomes, where they suppress mTORC1 signalling and 
thus induce autophagy in response to ROS [100]. Moreover, peroxisomal ROS induce 
selective autophagy of peroxisomes themselves (pexophagy) [101]. Ataxia-telangiectasia 
mutated (ATM), a serine/threonine kinase responsive to DNA damage, is also activated 
at peroxisomes in response to peroxisomal ROS to induce autophagy and pexophagy 
[102]. It also has been suggested that peroxisomal ROS serve as a measure for quality 
control of the organelle’s function [103].  
Use of a peroxisome-targeted H2O2 sensor revealed that peroxisomal redox milieu is 
kept reductive at steady-state despite abundant ROS productions [104]. This can be 
attributed to abundant peroxisome-resident antioxidative enzymes such as catalase, 
SOD1, SOD2, PRDX1, PRDX5, epoxide hydrolase, a peroxisomal membrane protein 20 
(PMP 20), and potentially a GPX [105]. Although no subtype of GPX has been identified 
in mammals as of yet, Gpx1 has been found in the peroxisomal matrix in yeast [106]. 
Indeed, the neuronal-specific ablation of peroxin 5 (Pex5, a peroxisomal biogenesis factor) 
causes peroxisome dysfunction and axonal myelin loss without causing oxidative stress 
in the central nervous system [107]. Furthermore, deficiency of PEX5 and PEX12 shifts the 
localisation of catalase from peroxisome to cytoplasm, and protects cells from oxidative 
damage by preferentially removing cytosolic ROS [108]. Thus, although peroxisomes are 
a significant source of ROS, they do not seem to be a critical source of oxidative stress, 
unless their multiple ROS quenching enzymes fail collectively. 
3.3. Nuclear ROS/H2O2 
The nucleus is the most reducing organelle in the cell [109], a fact not incongruous 
with its function of storing DNA, a most precious and oxidation sensitive cellular 
component. The reductive nuclear milieu is thought to be fuelled by thiol reductants such 
as thioredoxin-1 (TRX1), GPXs, PRDXs, glutathione (GSH) and specific isoforms of 
glutathione S-transferases. These reductants seem to scavenge nuclear ROS and function 
in the nucleus as well as other subcellular localisations. For instance, TRX1 localises to 
both nucleus and cytosol at steady state. However, in the presence of excess ROS, TRX1 
preferentially localises in the nucleus [110]. Redox potential shift of nuclear TRX1 (about 
60 mV oxidation from −300 mV at steady state) indicates that TRX1 attends to the oxidative 
stress in the nucleus [110]. Moreover, cytosolic TRX1 can interact with apoptosis-inducing 
factor (AIF) by forming a disulphide bond that facilitates delivery of AIF to the nucleus 
[111]. After this delocalisation, the reduction of TRX1–AIF complex releases AIF in the 
nucleus where it functions to promote apoptosis.  
GSH accumulates in the nucleus during cell proliferation and spreads throughout 
the cell when cells are confluent. [112,113]. It can be speculated that this serves as a 
defensive measure to protect the nucleus from oxidative stress, as intracellular ROS 
increase during mitosis [114]. Indeed, depletion of GSH impairs cell proliferation [115]. 
GSH not only directly removes nuclear ROS but also introduces glutathionylation to 
nuclear proteins, such as histone H3, to regulate nucleosome stability by blocking the 
irreversible oxidation of cysteine residues [116]. The level of glutathionylation of H3 is 
high in rapidly proliferating cells such as cancer cells and low in aged cells, suggesting 
this redox event may be relevant to ageing and diseases. 
Despite the abundance of nuclear reductants, ROS can unavoidably oxidise DNA in 
the nucleus. 8-Oxo-2’-deoxyguanosine (8-oxo-dG) is the most common product of DNA 
oxidation and has long been considered a useful, if somewhat biologically uninteresting, 
marker of oxidative damage. However, studies using genetic ablation of 8-oxoguanine 
DNA glycosylase 1 (OGG1), an enzyme that binds and removes 8-oxo-dG, have 
demonstrated a direct relevance of 8-oxo-dG to physical dysfunctions such as age-
associated neuronal loss and susceptibility to a dopaminergic toxin 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) [117,118]. Such phenotypes are likely mediated by 
DNA methylation status because 8-oxo-dG recruits a DNA demethylase ten-eleven 
translocation 1 (TET1) via OGG1 [119]. Indeed, a negative correlation between 8-oxo-dG 
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and 5-methyl cytosine (5mC), a methylated cytosine involved in gene transcriptions and 
various disorders, has been reported in gliomas [120]. Moreover, some gene expressions 
are upregulated by 8-oxo-dG on their loci promoter [121–127]. 
NOX4 appears as a significant nucleus-intrinsic source of ROS. Nuclear ROS 
emanating from NOX4 have been demonstrated to cause DNA damage, relevant to 
diseases such as myelodysplastic syndromes and viral infection [128,129], with a 
conceivable extension to neurodegeneration-associated DNA damage. Knockdown of 
NOX4 in human endothelial cells diminishes DNA damage and expanded cellular 
lifespan, displaying a strong relevance to senescence [130]. Intriguingly, NOX4 activity is 
negatively regulated by FYN, a tyrosine kinase belonging to SRC family kinases, implying 
programmed regulation of nuclear ROS by NOX4 as a result of cellular signalling, which 
seems to be relevant to cardiac remodelling [131]. 
3.4. Golgi ROS/H2O2 
There are fewer reports related to ROS production and oxidative stress in the Golgi 
apparatus than perhaps any other organelle. Since the main functions of the Golgi are 
secretory proteins’ glycosylation and sorting, studies exploring redox reactions in this 
compartment are relatively infrequent. However, the Golgi’s oxidative environment, 
which is equivalent to that of the ER, supports the plausibility of ROS production in this 
compartment [132]. 
Quiescin-sulfhydryl oxidases (QSOXs), flavin-linked sulfhydryl oxidases, are the 
most likely candidate for Golgi ROS production. All QSOX isoforms possess an ER signal 
peptide and are transported from the ER to the Golgi like generic secretory proteins 
lacking ER retention signals. Immunohistochemical analysis has also indicated a 
significant Golgi localised pool of this protein [133–136]. QSOX isoforms consist of two 
thioredoxin domains containing CxxC motifs and FAD-binding domain at the N-
terminus. As such, they can oxidise thiol groups to form disulphide bonds with the 
reduction of oxygen and production of H2O2, much like PDI and ERO1 in the ER [137]. 
Indeed, a recent report demonstrates QSOX1-dependent H2O2 production in human 
placenta-derived trophoblast and involvement of this protein in the pathogenesis of 
preeclampsia [138]. On the other hand, QSOX1 overexpression protects rat 
pheochromocytoma PC12 cells from oxidative stress-induced cell death, although it has 
also been reported to slow down cellular proliferation [139], hence potential benefits of 
QSOXs (and Golgi ROS in general) may depend on tissue and cell type. Moreover, 
upregulation of QSOXs expression is found in several types of cancers such as breast, 
pancreas, and prostate cancers, suggesting the relevance of this gene to cancer 
development [140,141]. Interestingly, higher expression of QSOX1 seems to reduce 
tumorigenesis and is associated with better outcomes for breast cancer patients (relations 
to known functions of QSOXs remains unclear) [142]. Exogenously expressed QSOX1 
restores impaired viability and disulphide bond formation capacity in Ero1p deficient 
yeast, suggesting that QSOX can rectify oxidative folding defects in proteins that, 
notwithstanding the ER quality control system, make it to the Golgi [136]. On the other 
hand, QSOX1 knocked-down fibroblasts fail to incorporate an extracellular matrix (ECM) 
protein—laminin, but not collagen IV and fibronectin [133]. Markedly, this defect is 
rescued by the addition of recombinant QSOX1 to the cell culture media [133]. These 
suggest that QSOX1, and its single-chain arrangement of ERO1 and PDI equivalents may 
specialise on a subset of secretory proteins and act extracellularly. 
The existence of other redox enzymes further implies the importance of redox 
regulation in the Golgi. In yeast, glutaredoxin 6 and 7 (Grx6, Grx7) are found to locate to 
the cis-Golgi preferentially [143]. Grx6 localises at both the ER and the Golgi, and Grx7 
predominantly localises at the Golgi. The glutaredoxin family are thought to play roles in 
detoxification of oxidative damage together with GSH, GPXs, and NADPH, preventing 
H2O2 production [144]. The Golgi is apparently protected from damage by Grx6 and Grx7 
upregulation in response to several stresses such as sodium and peroxides (as well as 
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calcium, specifically for Grx6), but not in response to heat shock and osmotic stress [145]. 
Although mammalian orthologs of these genes have not yet been identified, similar 
enzymes may exist that determine the level of H2O2 in the Golgi. 
In addition to the above-mentioned proteins, one isoform of NOS may be considered 
as another source of H2O2 in the Golgi. The NOS family are the enzymes that catalyse the 
production of NO from L-arginine and consists of three isozymes: neuronal NOS (nNOS), 
cytokine-inducible NOS (iNOS), and endothelial NOS (eNOS). Of these, eNOS is reported 
to locate to the Golgi membrane as well as the plasma membrane caveolae in endothelial 
cells [146–148]. All NOS proteins require dimerisation and several cofactors, such as 
nicotinamide adenine dinucleotide phosphate (NADPH), flavin adenine dinucleotide 
(FAD), flavin mononucleotide (FMN), calmodulin (CaM), Haeme, and 
tetrahydrobiopterin (BH4). Although NOS-derived NO underlies productions of reactive 
nitrogen species (RNS), a subset of free radicals, uncoupled eNOS resulting from L-
arginine and/or BH4 deficit, lead to the production of superoxide and subsequent H2O2 
(and molecular oxygen). This reaction can occur spontaneously or as SOD-catalysed 
dismutation [149,150]. 
The biological consequences of H2O2 produced in the Golgi are still elusive. Recently, 
a novel Golgi-targeted H2O2 specific probe termed Np-Golgi has been developed and 
revealed augmented H2O2 in the Golgi in hypertensive mice [151]. 
4. ROS/H2O2 and Neurodegeneration 
Oxidative stress is a hallmark of several diseases, including dementia and related 
neurodegeneration pathologies. Among ROS, H2O2 is often considered as the central 
player of redox-regulated events disrupted in neurodegenerative disorders [152–154]. A 
direct link between ROS and disease is provided by the pathology associated with SOD, 
an enzyme that plays a role in redox homeostasis by converting superoxide anion radicals 
into H2O2 and oxygen. Mutations in SOD1 have been shown to cause Amyotrophic Lateral 
Sclerosis (ALS) [155]. SOD1 aggregation in the motor neurons seems to be caused by 
oxidation of two of its free cysteines in the mitochondria where oxidative stress may occur 
[156]. Moreover, the excess activity of SOD1 due to a third copy of its encoding gene in 
Down syndrome results in the accumulation of H2O2 that may reach toxic levels sufficient 
to promote neuronal death [157]. An extensive body of evidence implicates oxidative 
stress in Alzheimer’s Disease (AD). In particular, peroxiredoxin levels are altered in AD, 
and lipid peroxidation is found in positive correlation with brain amyloid beta (Aβ)-
plaque load (the hallmark and genetic determinant of AD), suggesting a contribution of 
ROS to AD pathogenesis [158,159]. Furthermore, in Huntington’s disease, oxidative 
damage compromises low-molecular-weight antioxidant metabolism (i.e., reduced 
cysteine, GSH levels [160–163], and the uptake of reduced ascorbate [164,165]) and 
elevates the production of free radicals. Abundant evidence also suggests redox 
imbalance in other neurodegenerative diseases such as Parkinson’s disease [160], and in 
prion pathology, where a burst of ROS accompanies neurodegeneration [166].  
Thus, the substantial association of ROS with neurodegeneration suggested the use 
of antioxidants as a therapeutic strategy. Scavenging ROS by administration of 
antioxidants has been considered as a valid therapeutic strategy for several diseases, 
including neurodegeneration. For instance, trolox (a water-soluble vitamin E analogue) 
decreases aggregation of mutant SOD1 (SOD1G86R), which is a causing factor of familial 
ALS, in vitro [167]. Ascorbic acid (vitamin C) and a natural antioxidative compound 
berberine-derivative can suppress Aβ aggregation and thus AD pathology [168,169]. In 
addition, in vivo studies have demonstrated neuroprotective effects of some antioxidants, 
such as rosmarinic acid, coenzyme Q10, and α-tocopherol (vitamin E), in AD, PD, and 
Down syndrome animal models, respectively [170–173].  
However, despite these encouraging results using antioxidants as neuroprotectants 
in cell systems [174], beneficial outcomes at the organism level are inconsistent and, in 
large part, disappointing [175–177]. The reasons for those failures are not immediately 
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clear and may have to do with their effective bioavailability and/or antioxidants’ effects 
on physiological roles of ROS in cell signalling, (H2O2, in particular [178,179]). Significant 
antioxidant beneficial effects against neurodegeneration are predominantly seen at 
concentrations nearing their toxicity range when redox-dependent vital signalling 
pathways are also likely to be perturbed [176]. Developing organelle-selective 
antioxidants such as 2-[2-(triphenylphosphonio)ethyl]-3,4-dihydro-2, 5,7,8-tetramethyl-
2H-1-benzopyran-6-ol bromide (TPPB) and MitoQ, mitochondria-targeting antioxidants, 
may half-circumvent some of these limitations [180,181]. 
Rescuing redox homeostasis poses a challenge ahead to effective treatments against 
oxidative stress, which requires targeted strategies that are often confounded by the low 
specificity of most antioxidants in general. Favourably, metabolic antioxidants acting on 
specific metabolic transformations seem to have exerted alleviating effects in several 
animal models of neurodegenerative diseases [176]. Specific examples in cultured cell 
models include the apparent benefit afforded through modulating ROS-detoxifying 
selenoenzymes such as glutathione peroxidases, thioredoxin reductases and 
selenoprotein P [182–184].  
Another major hurdle in developing neuroprotective antioxidants seems to be their 
low blood–brain barrier permeability [177]. ROS are short-lived species due to their high 
reactivity. Some are able to oxidise cysteine and methionine residues, the DNA base 
guanine is prone to oxidative damage by ROS, lipids can undergo peroxidation, and even 
carbohydrates are prone to oxidative degradation and depolymerisation [160]. Quenching 
of ROS by antioxidants to prevent oxidative damage requires fast kinetics of reduction, 
which are not a given for all antioxidants. The problem may be further aggravated by 
limited bioavailability of antioxidants at the relevant location. For instance, quenching of 
H2O2 by reduced glutathione in the ER becomes kinetically competitive with enzyme 
catalysis only at 0.23 µM of H2O2 [13]. Thus, slow kinetics of antioxidant-ROS reactions 
may permit oxidative damage prior to ROS quenching events. 
The challenge posed is to nullify disease-relevant ROS with spatiotemporal 
specificity whilst leaving physiological ROS intact, which requires the drawback of 
antioxidant’s low-specificity to be circumvented. In targeting disease-relevant enzymatic 
sources of ROS, ROS-toxifiers (that convert relatively non-toxic ROS to more reactive 
species) or proteins that repair other oxidatively damaged proteins has been proposed as 
a more rational strategy to interfere with ROS than the use of antioxidants [185]. 
Understanding intracellular ROS–source pathways is a key to informing such strategies. 
Reports establishing a connection between oxidative stress and neurodegenerative 
disorders are innumerous and very disparate regarding a rational and causative link 
between them. Whether oxidative stress elicits neurodegeneration or is a consequence of 
neuronal cell death triggered by a combination of genetic and epigenetic factors and 
environmental interactions is still a matter of debate. The table below compiles a selection 
of findings on these relationships (Table 1).  
Table 1. Potential relations between oxidative stress and neurodegenerative disorders. 
Neurodegenerative 
Disorder Possible Source of Oxidative Stress Cell Component Affected Reference 
Parkinson disease Not determined Oxidized DJ-1 1 protein [186] 
 H2O2/rotenone/6-hydroxydopamine Parkin [187] 
 
Ca2+ influx through L-type 
channels/α-synuclein intracellular 
inclusions 
Mitochondrial oxidant stress [188,189] 
 NADPH oxidase α-synuclein [190] 
 NOS 2 S-nitrosylation of PDI 3 [191] 
 Not determined Depletion of GSH [192–194] 
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 Intrastriatal dopamine injections Protein-bound cysteinyl catechols/Loss of tyrosine hydroxylase [195] 
 Loss of dopamine homeostasis Inhibition of NADH oxidase/mitochondrial dysfunction [196] 
 Formation of the hexanoyl dopamine adduct Mitochondrial abnormality/apoptosis [197] 
 α-synuclein oligomer-induced ROS production Depletion of GSH [198] 
 α-synuclein oligomers Mitochondrial dysfunction [199] 
 Not determined Mitochondrial respiratory-chain Complex I [200] 
 Iron deposition in deep brain nuclei Fibrillation of α-synuclein/dopaminergenic neurodegeneration [201,202] 
 Inflammogen lipopolysaccharide/ NOS 2 and NADPH oxidase 
Aggregated nitrated α-
synuclein/upregulation of inflammatory 
markers 
[203] 
 Extracellular aggregated α-synuclein 
Activation of NADPH oxidase/microglial 
activation [204] 
 Activation of NOS 2 Decrease in parkin sulfhydration/increase in parkin nitrosylation [205] 
 Nitric oxide S-nitrosylation of Prx2 4 [206] 
Alzheimer’s disease Not determined Oxidized DJ-1 1 protein [186] 
 Aβ plaques Neurites [207] 
 Aβ plaques Reduced GSH levels/Decreased SOD activity [208] 
 Aβ plaques Mitochondrial protein import channels [209] 
 Not determined Nuclear and mitochondrial DNA damage [210] 
 Increase in BACE1 5 activity Lipid peroxidation [211] 
 Not determined JNK/SAPK 6 dysregulation [212] 
 Aβ oligomers 
Inhibition of EAAT3 7-mediated cysteine 
uptake/decreased GSH levels/decreased 
DNA methylation 
[213,214] 
 Inhibition of GSH synthesis Increased levels of tau phosphorylated [215] 
 Age-dependent Mitochondrial DNA deletion [216] 
 Not determined Loss of REST 8 [217] 
 NOS 2 S-nitrosylation of PDI 3 [191] 
 Aβ(1-42) oligomers Activation of NMDARs 
9/increase in Nitric 
oxide [218] 
Huntington’s 
disease Age-dependent Mitochondrial DNA damage [219] 
 Not determined Cytosolic SOD 
10 activity/nuclear 
DNA/oxidative phosphorylation enzymes [220] 
 Not determined Cu/Zn-SOD 
10 activity/glutathione 
peroxidase activity/mitochondrial DNA [221] 
 Not determined Reduced GSH levels/plasma lipid peroxidation [222] 
 Mitochondrial Ca
2+ signalling and 
superoxide generation Mitochondrial DNA damage [223] 
 Depletion of cystathione γ-lyase 11 




 Impaired cysteine biosynthesis and transport 
Failure of activating transcriptional factor 4 
(ATF4) induction [163] 
 Uptake of vitamin C 
Impaired trafficking of vitamin C 
transporters/impaired glucose transporter 
GLUT3 to the membrane 
[164,165] 
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 Iron metabolism Not determined [224] 
 Age-dependent Oxidative DNA damage (CAG trinucleotide expansion) [225] 
 Reduced activity of Nrf2 12 Impaired mitochondrial dynamics/decreased mitochondrial fusion [226] 
 Impaired function of PGC1α 13 Mitochondrial dysfunction [227] 
 Not determined Reduced levels of GSH [228] 
Amyotrophic lateral 
sclerosis 
Mutations in Cu/Zn SOD 10 (familiar 
cases) 
Increased cytosolic and mitochondrial 
ROS/impaired mitochondrial respiration [229,230] 
1 Ubiquitously expressed protein of the DJ-1/ThiJ/PfpI superfamily whose biochemical function is unknown; 2 Nitric oxide 
synthase; 3 Protein disulphide isomerase; 4 Peroxiredoxin-2; 5 β-secretase, β-site amyloid precursor protein cleaving enzyme 
1; 6 c-Jun N-terminal kinase/Stress activated protein kinase; 7 Excitatory amino acid transporter 3; 8 Repressor element 1-
silencing transcription factor, represses genes that promote cell death and induces expression of stress response genes; 9 
N-methyl-D-aspartate-type glutamate receptor; 10 SOD—superoxide dismutase; 11 Biosynthetic enzyme for cysteine; 12 
Erythroid 2-related factor 2, a master transcriptional regulator of the cellular antioxidant stress response; 13 Peroxisome 
proliferator-activated receptor γ coactivator 1α, a master transcriptional co-regulator of mitochondrial biogenesis and 
metabolism and antioxidant defences. 
4.1. ER H2O2 and Neurodegeneration 
The extent of UPR activation strongly correlates with the pathology of human 
patients carrying neurodegenerative diseases [231], and neurodegeneration-causing 
factors, such as Aβ1–42 oligomer and tau, can also augment UPR [232,233], suggesting that 
excess UPR (ER stress) synergically contributes to the development of neurodegeneration. 
Given that UPR is originally an adaptive signalling pathway that governs quality control 
of proteins in the ER, target genes of UPR should be expected to be neuroprotective. PDI 
in particular, is considered as a potential target UPR-gene. Indeed, PDIA3 (ERp57) 
protects from ischemia-induced brain damage [234]. Further, upregulation of PDI 
expression in the central nervous system (CNS) seems to be a common feature observed 
in the patients and animal model of several neurodegenerative diseases such as AD, PD, 
ALS, and HD [235–239]. Interestingly, reversible/irreversible inhibitors of PDI show 
neuroprotective effects in vitro [240,241]. In addition, inhibitions of PDI by CCF642 or 
LOC14 appear neuroprotective in a mouse model of Experimental autoimmune 
encephalomyelitis (EAE) and HD [242,243]. ERO1 inhibitor EN460 also antagonises 
neurotoxicity [244]. Seemingly paradoxical observations that both inhibitors of these 
proteins and their upregulation show neuroprotective effects [169,245,246] can be 
reconciled under the assumption that their activity is crucial, but their by-product-ROS is 
hazardous. Consistently, small molecule antioxidants relieve not only oxidative load but 
also ER stress [247], probably at least in part by removing PDI and ERO1-derived ROS. 
Further, ER-antioxidative enzymes benefit neuronal health: PRDX4 can protect from 
Aβ oligomer- or glutamate-mediated cell death presumably by suppressing ER stress 
[38,248]. While GPX7 deficient mice show an accelerated, aging-related 
neurodegeneration, accompanied by elevated ROS, in spinal motor neuron [245]. A brain 
transcriptome analysis reveals that this gene is significantly upregulated in response to 
neurotoxin MPTP [246,249]. 
Together these observations suggest that if excess ER-ROS can be eliminated from 
the cell, the beneficial outcomes of UPR should be expected to antagonise the 
neuropathophysiology more effectively (Figure 2). 




Figure 2. Schema of unfolded proteins response (UPR)-induced neurodegeneration and potential 
therapeutic strategies. UPR activated by a variety of factors, such as single nucleotide 
polymorphisms (SNPs) as genetic factors and aging or metabolic dysfunction as environmental 
factors, augments the expressions of target genes such as PDI and ERO1, and enhances the 
oxidative folding capacity of the ER. This can reduce the accumulation of unfolded proteins and 
results in neuroprotection, whereas excess H2O2, which is concomitantly produced by this process, 
exacerbates neurodegeneration as an oxidative stress agent. Inhibitors against PDI or ERO1 (such 
as CCF642, LOC14, and EN460) and antioxidants are considered promising in mitigating the 
development of neurodegenerative pathology by reducing ER-derived H2O2. 
5. Conclusions and Perspectives 
In this review, we have outlined the sources and known functionalities of ROS from 
the ER and other organelles. Organelles harbour pathways that produce ROS as a by-
product of redox reactions and/or to be utilised as a signalling factor. Uniquely, the ER 
utilises a ROS, H2O2 to directly fuel is anabolic activity—the oxidative protein folding. 
This organelle satisfies its own demand of ROS by internally producing abundant H2O2, 
on a scale that may well exceed that of any other organelle. As the ER constitutes a major 
source of ROS in the cells, the organelle’s homeostasis often correlates with cellular redox, 
explaining the simultaneous presence of ER stress and oxidative stress in the process of 
ageing and diseases. 
It is plausible that antagonising ROS with antioxidants may have utility in alleviating 
the oxidative damage in certain disease states. However, the use of antioxidants as a 
therapeutic strategy is still controversial due to the uncertainty of their usefulness in 
humans. This may be because the comprehensive scavenging of systemic ROS not only 
relieves oxidative stress but also deprives the physiological advantages of ROS, which 
drive biological reactions by physiological oxidation of target molecules. Although 
distinguishing ROS benefit and toxicity in vivo is a significant challenge, this dilemma 
must be resolved to some extent by source-selective suppression of excessive ROS. As 
mentioned in this review, some molecules have indeed been developed such as TPPB and 
mitoQ (mitochondria-targeting antioxidants) and CCF642, LOC14, and EN460 (PDI and 
ERO1 inhibitor, respectively) to decrease local ROS productions. Therefore, controlling 
spatial ROS productions will be a future focus for providing antioxidants a utility as 
therapeutics. Finally, visualisation of ROS in live-cells has become clearer by the 
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development of organelle-targeted genetically encoded redox sensors, such as roGFP and 
HyPer, as well as chemical probes. Most of these probes can detect ROS reversibly, 
allowing the monitoring of homeostatic ROS production and consumption. Indeed, these 
techniques also capture the redox state of tissues in vivo [250,251]. In addition to these 
tools, further development of biosensor implementations of image acquisition technology 
such as two-photon microscopy, super-resolution microscopy, and single-molecule 
analysis will likely enable mapping of physiological ROS with higher spatiotemporal 
resolution. The elucidation of local ROS functionality will be expected to provide new 
clues to aid our understanding of the pathophysiology not only of neurodegenerative 
diseases, but also ageing, cancer, and other related diseases. 
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Glossary 
Superoxide (O2.-) 
A radical ROS produced by the one-electron reduction of 
molecular oxygen. It is converted to hydrogen peroxide and 








Highly reactive and short-lived radical. Its production is driven 
by Fenton reaction, between ferrous ion (Fe2+) and hydrogen 
peroxide. 
Redox potential 
Expressed in millivolts (mV), a measure of redox state that reflects 
the tendency of a chemical to receive/donate electrons, and 




An antioxidant enzyme catalysing dismutation of superoxide to 
hydrogen peroxide and molecular oxygen. SOD family consists of 
Cu/Zn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3). 
Mutations in the SOD1 gene affect approximately 20% of familial 
amyotrophic lateral sclerosis (ALS). 
Peroxiredoxin (PRDX) 
An antioxidant enzyme scavenging peroxides including H2O2. 
PRDX family consists of six isoforms (PRDX1-6). PRDX4 is 
localised in the ER. 
Glutathione 
peroxidase (GPX) 
An antioxidant enzyme scavenging H2O2 as well as lipid 
peroxides by utilising reduced glutathione. GPX family consists of 
eight isoforms (GPX1-8). GPX1-4 and GPX6 contain an active site 
selenocysteine (selenoproteins). GPX7 and GPX8 are localised in 
the ER. GSH peroxidase activity of GPX7 and GPX8 is low.  




An abundant antioxidant tripeptide consisting of alanine–
cysteine–glutamate (with cysteine and glutamate linked by 
gamma–glutamyl bond). Reduced glutathione (GSH) drives GPXs 
reactions and as a result GSH is converted to the oxidised form 
(GSSG), in which two molecules are bound by disulfide bond. 
GSSG is recycled by reducing by glutathione reductase (GR). 
Catalase 
An antioxidant enzyme that scavenges H2O2. The iron-bound 
heme group in the active site catalyses the conversion of H2O2 to 




An ER chaperone possessing oxidoreductase activity via CXXC 
catalytic motif-containing thioredoxin domains. Catalyses protein 
disulphide bond formation and isomerisation during folding of 
ER client proteins. 
ER oxidoreductin 1 
(ERO1) 
A sulfhydryl oxidase that supplies oxidising equivalents to 
recycle PDI, in the process ERO1 produces H2O2 by reducing O2 
with its active site (CXXCXXC motif/flavin adenine dinucleotide 






An enzyme catalysing the production of a superoxide by 
transferring one electron to oxygen from NADPH. The NOX 
family consists of NOX1~NOX5, Dual oxidase 1 (DUOX1) and 
DUOX2. Among NOXs, NOX4 preferentially produces H2O2 
rather than superoxide. 
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